GET DAILY SIGNALSLumexa Imaging Holdings (LMRI) Analyst Targets Point to +22% Upside
Key Takeaways
- The central target of $17 is the arithmetic mean of seven current analyst price targets, which range from a low of $13 to a high of $19.
- With shares trading near $14, reaching $17 would require roughly a 22% advance from recent levels.
- All seven reviewed targets carry Buy or equivalent ratings, reflecting a broadly bullish view of outpatient diagnostic imaging demand.
- The strongest supporting factors are a fragmented, growing imaging market, a hospital-to-outpatient shift, and an AI-driven growth strategy.
- The biggest risks are that LMRI remains unprofitable, carries meaningful leverage, and has been highly volatile since its late-2025 IPO.
- Readers can explore the ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages for additional detail.
- For AI-driven market scanning, readers can explore Trending AI Robots.
The Analyst Consensus on LMRI
Lumexa Imaging Holdings, Inc. (LMRI) is a Raleigh, North Carolina-based operator of outpatient diagnostic imaging centers that went public on the Nasdaq in December 2025. The company runs roughly 184 centers across 13 states, offering MRI, CT, PET, X-ray, ultrasound, and mammography services.
Across recent sell-side coverage, seven credible, current analyst price targets could be verified with named firms and dates: Truist ($18, initiated October 2026), J.P. Morgan ($18, maintained August 2026), KeyBanc ($18, initiated September 2026), Wells Fargo ($19, maintained August 2026), Raymond James ($17, reiterated September 2026), Deutsche Bank ($16, lowered from $22 in August 2026), and Barclays ($13, maintained August 2026). The arithmetic mean of these seven targets is $17, with an approximate low-to-high range of $13 to $19.
This figure is a calculated average rather than an official published consensus. Notably, the range is wide—Barclays sits $4 below the high end—reflecting genuine disagreement about valuation and the pace of the company's path to profitability. Earlier, pre-IPO-era targets near $23 from Jefferies and Leerink were excluded as stale. Every recent rating reviewed is Buy or Overweight, but William Blair reiterated a Buy without a specific target. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where LMRI Stands Today and the Road to $17
With LMRI trading near $14 in recent sessions, a move to the $17 central target implies upside of about 22%—a substantial but not extraordinary move for a recently listed growth name. The stock's 52-week range of roughly $6.45 to $19.45 underscores how far shares have swung, and the current price sits well below that prior high.
The company generated trailing revenue of about $1.04 billion, up roughly 10% year over year, yet it remains loss-making, with a trailing net loss and negative EPS (earnings per share). Its August 2026 quarterly report was characterized as a strong beat with a reaffirmed 2026 outlook, which helped stabilize sentiment after a volatile stretch. The path toward the target therefore hinges less on near-term earnings and more on sustained revenue growth, operating leverage, and continued center expansion.
Factors That Could Support a Move Toward the Target
Several verified factors underpin the bullish case. Analysts point to a large, growing, and fragmented diagnostic imaging market with meaningful "white space" for consolidation. KeyBanc cited "powerful secular drivers," including the ongoing hospital-to-outpatient shift and rising demand for advanced imaging, while Truist highlighted Lumexa's joint-venture playbook and AI integration approach. A strong second-quarter beat and a reaffirmed full-year outlook, noted by William Blair, provide a fundamental anchor. If revenue growth compounds and the company progresses toward profitability, the roughly 22% gap to the target could narrow.
Risks That Could Keep the Target Out of Reach
The principal obstacles are financial and structural. LMRI is not yet profitable, reporting a trailing net loss and negative diluted EPS, and it carries a relatively high debt-to-equity ratio. A high-leverage, loss-making profile leaves little margin for error if volumes soften or reimbursement pressure rises. Barclays' low-end $13 target—only modestly above current levels—reflects skepticism about valuation and the speed of margin improvement. The stock's extreme volatility since its IPO, including a drop from near $19.45 to a low around $6.45 before recovering, shows that sentiment can shift quickly. Macroeconomic pressures on healthcare utilization or interest rates could further weigh on a growth-oriented, rate-sensitive name.
Technical Levels Worth Watching
From a market-structure perspective, the $19.45 52-week high stands out as the most durable resistance zone, representing the stock's prior peak before its sharp decline. The $6.45 52-week low marks major long-term support. Shares have recovered into the low-to-mid teens, and round-number levels near $15 and $17 may act as psychological waypoints on any move toward the target. Because LMRI has only traded publicly since December 2025, its technical history is limited, and these levels should be treated cautiously. I reviewed recent patterns through Tickeron’s AI Pattern Search Engine for additional context on support and resistance zones.
Time Horizon and Key Metrics to Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms do not always disclose a precise timeframe and may differ. Investors should monitor quarterly earnings and any updates to 2026 guidance, same-center volume growth, new center openings and joint ventures, analyst target revisions, and any commentary on reimbursement or interest-rate conditions. Progress toward breakeven profitability is likely the single most important variable for the stock's valuation. From what I see, tracking these elements closely will clarify whether the gap to the $17 target is narrowing.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For investors tracking LMRI alongside the broader market, the tool offers a way to stay alert to evolving momentum.
Final Assessment
The $17 central target for LMRI is a calculated average of seven current analyst targets spanning $13 to $19, implying a move of roughly 22% from recent levels. Support comes from secular imaging demand, a fragmented market, a strong recent quarter, and unanimous Buy ratings, while the counterweights are persistent losses, high leverage, and notable volatility. The wide analyst range reflects genuine uncertainty about how quickly the company can convert revenue growth into profitability. Investors should watch earnings, guidance, and center-expansion metrics to assess whether the distance to $17 is closing.
Exploring AI Tools for Research
In my own analysis, I often turn to Tickeron’s AI Trading Bots to test different scenarios and see how automated strategies might respond to names like LMRI. The platform’s real-time signals and pattern recognition features provide a useful layer of data when evaluating volatility and momentum alongside traditional fundamentals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LMRI in upward trend: price rose above 50-day moving average on October 23, 2026
LMRI moved above its 50-day moving average on October 23, 2026 date and that indicates a change from a downward trend to an upward trend. In 4 of 4 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on LMRI as a result. In 11 of 13 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for LMRI just turned positive on October 06, 2026. Looking at past instances where LMRI's MACD turned positive, the stock continued to rise in 4 of 5 cases over the following month. The odds of a continued upward trend are 80%.
The 10-day moving average for LMRI crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +5.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where LMRI advanced for three days, in 38 of 46 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 15 of 19 cases where LMRI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LMRI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
LMRI broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.098) is normal, around the industry mean (4.142). P/E Ratio (-46.532) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.075) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. LMRI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LMRI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement